Given the favorable toxicity profile of hormonal therapy, we believe that our results, though based upon a small sample size, would support the use of hormonal therapy after resection of a solitary brain metastasis in patients with ER+ breast cancer. The gene discussed is ESR1; the disease is breast cancer.